The type 1 IGF receptor (IGF-IR) is activated by two ligands, IGF-1 and IGF-2, and by insulin at supraphysiological concentrations. It plays a significant role in the growth of normal and abnormal ...

With potential to have lonigutamab as a possible best-in-class anti-IGF-1R drug for TED, plus moving rapidly into phase 3 clinical testing, I believe that investors could benefit with any ...

Veligrotug is an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody. The THRIVE-2 study (NCT06021054) of veligrotug in patients with chronic TED is fully enrolled ...

智通财经APP获悉，天风证券发布研究报告称，维持信达生物(01801)“买入”评级，考虑到公司已上市产品持续放量，多条研发管线即将进入产品收获期，将2024和2025年的收入预期分别从72.25、91.93亿元上调至79.70、102.35亿元，预计 ...

Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the ...

VRDN-001 is also IV administered and is a monoclonal antibody, but also acts as a full antagonist of the IGF-1R signaling pathway. This should provide it with some advantages over Tepezza (above).

【解剖大盘】A股终于开盘，经过国庆的发酵，开盘即出现井喷。沪指高开10.13%，达到3674.4点，创业板指高开幅度高达18.44%。成交量首次突破三万亿，达到3.45万亿的历史巨量，上涨股票超5000只，市场呈现一片牛市欣欣向荣景象。而港股这边画风 ...

This optimism is founded on the drug’s mechanism of action being already de-risked and based on initial clinical data suggesting VRDN-001’s robust antagonism of IGF-1R. Furthermore ...

Viridian Therapeutics (VRDN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Piper Sandler维持Acelyrin Inc (NASDAQ: SLRN)的"增持"评级和20.00美元的目标价。 该公司的立场是在预期2024年底或2025年初将获得lonigutamab的进一步Phase 1/2数据。 根据Acelyrin的管理团队表示，最近的ESOPRS数据突显了lonigutamab对甲状腺眼病 (TED)患者生活质量的显著影响。

A list of suggestions for customizing IGF-IR targeting is provided in the Executive summary. One has to seriously consider the hypothesis that cancer cells can acquire the ability of using one ...